Oct-25-16 Antibe Therapeutics Announces CEO Letter to Shareholders
Oct-17-16 Antibe Therapeutics Confirms Non-Addictive Properties for its Second Pipeline Drug, ATB-352, a Potent, Non-Addictive Pain-Killer
Oct-14-16 Antibe Therapeutics Announces Payment in Kind Election
Oct-11-16 Antibe Therapeutics Announces Launch of Strategic Growth Initiative in the U.S. Market for Dental Biologics
Sep-22-16 ATB-346 Shows Promising Results in Experimental Melanoma
Sep-07-16 Antibe Therapeutics to Present at 2016 Rodman & Renshaw Global Investment Conference
Aug-29-16 Antibe Therapeutics Reports Q1 2017 Interim Financial and Operating Results
Aug-16-16 Antibe Therapeutics Announces the Launch of Neomem® FlexPlus, a High-Performance Barrier Membrane for Oral Surgery
Aug-08-16 Antibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in Osteoarthritis
Jul-29-16 Antibe Therapeutics Reports 2016 Year-End Financial and Operating Results
Jul-19-16 Antibe Therapeutics Announces the Appointment of New Board Member and Provides Update on Phase 2 Trial of ATB-346
Jun-20-16 Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,455,000
Jun-10-16 Antibe Therapeutics Raises $968,500 in First Tranche of Non-Brokered Private Placement
May-30-16 Antibe Therapeutics Presenting Update on ATB-346 at International Hydrogen Sulfide Conference
May-02-16 Antibe Therapeutics to Present at 2016 Bloom Burton & Co. Healthcare Investor Conference
Apr-18-16 Antibe Therapeutics Announces the Launch of PentOS OI™ Putty, A High-Quality Bone Graft Substitute for Oral and Maxillofacial Surgery
Mar-31-16 Antibe Therapeutics Announces Appointment of The Giordano Group Inc as US-Based Investor Relations Consultant
Mar-09-16 Antibe Therapeutics Announces Grant of Stock Options
Mar-07-16 Antibe Therapeutics’ ATB-346 Receives Approval for Phase 2 Clinical Trial in Osteoarthritis Patients
Feb-29-16 Antibe Therapeutics Reports Q3 2016 Interim Financial and Operating Results